Literature DB >> 6314833

Human interferon production in tonsil and adenoid tissue cultures.

W J Richtsmeier.   

Abstract

Using Sendai virus as an inducer, tonsil lymphocytes produce alpha interferon (IFN-alpha) 1,000 times more potent than that reportedly induced using Newcastle disease virus in such lymphoid tissue. Alpha and gamma interferons can be produced from tonsil and adenoid lymphocyte cultures in amounts comparable with those produced from cultures of pooled peripheral blood lymphocytes. Lymphocytes from both tonsils and adenoids are equal in the amount of IFN each produces. The IFN-producing potential of lymphocytes appears constant in humans between the ages of 3 and 38 years and is not adversely affected during the first trimester of pregnancy. Since approximately one billion lymphocytes are obtained from each of these tissues, they represent a potential source of significant quantities of IFN for investigational use.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6314833     DOI: 10.1016/s0196-0709(83)80019-2

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  3 in total

1.  Racial disparities in Human Papillomavirus (HPV) associated head and neck cancer.

Authors:  Jose Jiron; Seema Sethi; Rouba Ali-Fehmi; Silvia Franceschi; Linda Struijk; Leen-Jan van Doorn; Wim Quint; Ikuko Kato
Journal:  Am J Otolaryngol       Date:  2013-09-28       Impact factor: 1.808

2.  Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity.

Authors:  Sanjib Chaudhary; Koelina Ganguly; Sakthivel Muniyan; Ramesh Pothuraju; Zafar Sayed; Dwight T Jones; Surinder K Batra; Muzafar A Macha
Journal:  J Natl Cancer Inst       Date:  2019-03-01       Impact factor: 13.506

3.  Immunohistochemical detection of co-localizing cytokine and antibody producing cells in the extrafollicular area of human palatine tonsils.

Authors:  S Hoefakker; E H van 't Erve; C Deen; A J van den Eertwegh; W J Boersma; W R Notten; E Claassen
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.